GLP-1 receptor agonist medications — including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — represent highly effective therapies for weight management and type 2 diabetes. However, like all potent pharmacological agents, they carry specific contraindications where the risks of therapy outweigh the benefits. Understanding these contraindications is essential for safe prescribing and for patients seeking to understand whether they are appropriate candidates for these medications.
Absolute Contraindications: When GLP-1 RA Must Not Be Used
Absolute contraindications are conditions where GLP-1 RA medications are definitively prohibited based on known serious safety risks.
1. Personal or Family History of Medullary Thyroid Carcinoma (MTC)
Medullary thyroid carcinoma (MTC) is a rare cancer arising from C-cells of the thyroid gland. In rodent studies at pharmacologically relevant doses, GLP-1 RA medications caused dose-dependent increases in thyroid C-cell tumors. While this has not been confirmed in humans, the FDA has mandated a black box warning on all GLP-1 RA medications: patients with a personal or family history of MTC must not use these drugs.
The mechanism is believed to involve GLP-1 receptor stimulation on thyroid C-cells, which are present in rodents at higher density than in humans. However, because the consequences of triggering MTC recurrence or development could be severe and potentially fatal, the absolute contraindication stands until human evidence definitively clarifies the risk. For a full discussion of thyroid considerations, see Thyroid Cancer Risk and GLP-1 RA.
2. Multiple Endocrine Neoplasia Type 2 (MEN2)
MEN2 is a hereditary syndrome caused by RET proto-oncogene mutations, characterized by MTC, pheochromocytoma, and hyperparathyroidism. Because MTC is a defining feature of MEN2, GLP-1 RA use is absolutely contraindicated in patients with known or suspected MEN2 syndrome. Genetic testing for RET mutations is relevant when there is a family history suggestive of MEN2.
3. Known Hypersensitivity to GLP-1 RA Components
Patients who have experienced severe allergic reactions (anaphylaxis, angioedema) to semaglutide, tirzepatide, or any excipient in the formulation must not receive these medications. Hypersensitivity reactions, while uncommon, have been reported and can be life-threatening.
Pregnancy and Planning for Conception
GLP-1 RA medications are contraindicated during pregnancy. Animal studies have shown dose-dependent fetal abnormalities and reduced fetal growth with GLP-1 RA exposure. The FDA recommends discontinuing GLP-1 RA medications at least 2 months before a planned pregnancy for injectable semaglutide (given its long half-life of approximately 1 week, allowing sufficient washout time). Given the interaction between GLP-1 RA and oral contraceptive absorption — as detailed in Drug Interactions with GLP-1 RA — additional contraceptive precautions are important for women of childbearing potential on these medications.
GLP-1 RA is also not recommended during breastfeeding, as it is unknown whether semaglutide or tirzepatide are excreted in human breast milk.
💡 💡 Clinical Pearl: Screening Questions Before Starting GLP-1 RA
Before initiating any GLP-1 RA medication, clinicians should screen for: personal or family history of MTC or MEN2; current or planned pregnancy; history of pancreatitis (acute or chronic); severe GI motility disorder; and known hypersensitivity. A thyroid examination and relevant family history documentation should be part of the baseline assessment. These few screening questions can prevent serious clinical harm.
Relative Contraindications: Proceed with Caution
Relative contraindications are conditions where GLP-1 RA may be used in some cases with careful monitoring and clinical judgment, but where the risk-benefit ratio requires individualized assessment.
1. History of Pancreatitis
GLP-1 RA has been associated with an increased risk of acute pancreatitis in post-marketing surveillance. The absolute risk appears low, but pancreatitis can be life-threatening in severe cases. Patients with a prior history of acute pancreatitis — particularly if idiopathic or without a clear reversible cause — represent a relative contraindication. Patients with chronic pancreatitis, advanced pancreatic disease, or high baseline triglycerides require particularly careful consideration. If pancreatitis is suspected during GLP-1 RA therapy, the medication should be discontinued. See Pancreatitis Risk with GLP-1 RA for a detailed discussion.
2. Severe Gastroparesis or Bowel Obstruction
Because GLP-1 RA significantly slows gastric emptying, they are relatively contraindicated in patients with pre-existing severe gastroparesis (delayed gastric emptying from any cause, including diabetic autonomic neuropathy) or a history of bowel obstruction. These conditions can be significantly worsened by further GI motility slowing.
3. End-Stage Renal Disease
Injectable semaglutide has been studied in patients with CKD and does not require dose adjustment for most stages of CKD. However, patients with severe renal impairment or end-stage renal disease (ESRD) on dialysis may have altered drug exposure and reduced tolerability. Oral semaglutide (Rybelsus) is not recommended in patients with severe renal impairment.
4. Severe Hepatic Impairment
Data on GLP-1 RA in severe hepatic impairment are limited. Caution is appropriate in patients with Child-Pugh class C cirrhosis or active severe liver disease.
5. Active Eating Disorders
Patients with active anorexia nervosa or restrictive eating disorders face particular risks with GLP-1 RA, as appetite suppression may exacerbate pathological food restriction. Careful psychiatric evaluation is required before considering GLP-1 RA in this population. See related discussion in Mental Health on GLP-1 RA.
💡 Frequently Asked Questions (FAQ)
Q1: If my mother had thyroid cancer, can I still take semaglutide?
A1: This depends on the type of thyroid cancer. Only medullary thyroid carcinoma (MTC) — and MEN2 syndrome involving MTC risk — represents an absolute contraindication. Papillary and follicular thyroid cancers (the most common types) are not a contraindication. Confirm the thyroid cancer type with your physician before initiating GLP-1 RA, as the family history details matter significantly.
Q2: How long before trying to get pregnant should I stop GLP-1 RA?
A2: Current guidance recommends stopping injectable semaglutide at least 2 months before planned conception, and tirzepatide similarly. This allows sufficient time for drug clearance before embryonic development begins. Discuss contraceptive planning carefully with your physician.
Q3: I had pancreatitis once, years ago — am I permanently excluded from GLP-1 RA therapy?
A3: Not necessarily. A single episode of pancreatitis with a clearly identified and resolved cause (e.g., gallstones that have been surgically treated) may not permanently exclude GLP-1 RA use. This is an individualized clinical decision requiring careful assessment by a knowledgeable physician, with discussion of risks and benefits and close monitoring if therapy is initiated.
📚 References & Sources
- FDA. (2021). Wegovy (semaglutide) Prescribing Information. U.S. Food and Drug Administration.
- Marso, S.P., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine, 375(19), 1834–1844.
- Monami, M., et al. (2014). Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, 103(3), 269–275.